Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Michel de Groot"'
Autor:
Hans J. P. M. Koenen, Ilse J. E. Kouijzer, Michel de Groot, Steffie Peters, Daphne Lobeek, Evelien A. J. van Genugten, Dimitri A. Diavatopoulos, Nienke van Oosten, Sanne Gianotten, Mathias M. Prokop, Mihai G. Netea, Frank L. van de Veerdonk, Erik H. J. G. Aarntzen
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
The upper respiratory tract (URT) is the entry site for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), from where it further disseminates. Early and effective adaptive immune responses are crucial to restrict viral replication and limi
Externí odkaz:
https://doaj.org/article/ecdef4ca01694886916ee3759709b92d
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Willemijn A. van Gemert, Michel de Groot, Harm Westdorp, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Abstract Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-fr
Externí odkaz:
https://doaj.org/article/d0eae2f7bc184b94b9f6863ede0c30e8
Autor:
Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastati
Externí odkaz:
https://doaj.org/article/05ea3477df904c7e9eba15f0eafa2c79
Autor:
Youssra Allach, Amina Banda, Willemijn van Gemert, Michel de Groot, Yvonne Derks, Melline Schilham, Alexander Hoepping, Lars Perk, Martin Gotthardt, Marcel Janssen, James Nagarajah, Bastiaan M. Privé
Publikováno v:
Cancers, Vol 14, Iss 9, p 2076 (2022)
Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) allows for accurate diagnosis and staging of prostate cancer (PCa). Compared to other PSMA PET tracers available, [18F]PSMA-1007 is predominantly excreted via the hepatob
Externí odkaz:
https://doaj.org/article/aa22253d722f49d083c9961cbd44e343
Autor:
Youssra Allach, Amina Banda, Willemijn van Gemert, Michel de Groot, Yvonne Derks, Melline Schilham, Alexander Hoepping, Lars Perk, Martin Gotthardt, Marcel Janssen, James Nagarajah, Bastiaan M. Privé
Publikováno v:
Cancers, 14
Cancers, 14, 9
Cancers; Volume 14; Issue 9; Pages: 2076
Cancers, 14, 9
Cancers; Volume 14; Issue 9; Pages: 2076
Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) allows for accurate diagnosis and staging of prostate cancer (PCa). Compared to other PSMA PET tracers available, [18F]PSMA-1007 is predominantly excreted via the hepatob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4443296cf753d532f52b0082dae02ef4
http://hdl.handle.net/2066/250230
http://hdl.handle.net/2066/250230
Autor:
Willemijn A. M. van Gemert, Andries M. Bergman, Constantijn H.J. Muselaers, Henk G. van der Poel, Walter Noordzij, André N. Vis, Patrik Zamecnik, Bastiaan M. Privé, Harm Westdorp, Inge M. van Oort, Michel de Groot, James Nagarajah, Martin Gotthardt, Marianne A. Jonker, Winald R. Gerritsen, Daniela E. Oprea-Lager, Niven Mehra, Wouter V. Vogel, Marcel J.R. Janssen, Jelle O. Barentsz, J. Alfred Witjes, J. Fred Verzijlbergen, Tom W. J. Scheenen
Publikováno v:
Trials, 22, 1
Trials, 22
TRIALS, 22. BMC
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Trials, 22(1):768. BioMed Central
Privé, B M, Janssen, M J R, van Oort, I M, Muselaers, C H J, Jonker, M A, van Gemert, W A, de Groot, M, Westdorp, H, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, van der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2021, ' Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer : the BULLSEYE trial ', Trials, vol. 22, no. 1, 768 . https://doi.org/10.1186/s13063-021-05733-4
Trials
Trials, 22
TRIALS, 22. BMC
Trials, Vol 22, Iss 1, Pp 1-4 (2021)
Trials, 22(1):768. BioMed Central
Privé, B M, Janssen, M J R, van Oort, I M, Muselaers, C H J, Jonker, M A, van Gemert, W A, de Groot, M, Westdorp, H, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, van der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2021, ' Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer : the BULLSEYE trial ', Trials, vol. 22, no. 1, 768 . https://doi.org/10.1186/s13063-021-05733-4
Trials
Background The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if 177Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free surviv
Autor:
Winald R. Gerritsen, Daniela E. Oprea-Lager, Constantijn H.J. Muselaers, Henk G. van der Poel, Marianne A. Jonker, Walter Noordzij, Marcel J.R. Janssen, Jelle O. Barentsz, Tom W. J. Scheenen, Inge M. van Oort, Michel de Groot, Niven Mehra, Wouter V. Vogel, Bastiaan M. Privé, J. Alfred Witjes, Patrik Zamecnik, Andries M. Bergman, Martin Gotthardt, J. Fred Verzijlbergen, André N. Vis, James Nagarajah
Publikováno v:
BMC Cancer
BMC Cancer, 20
BMC Cancer, 20, 1
Privé, B M, Janssen, M J R, Van Oort, I M, Muselaers, C H J, Jonker, M A, De Groot, M, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, Van Der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2020, ' Lutetium-177-PSMA-I &T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial ', BMC Cancer, vol. 20, no. 1, 884 . https://doi.org/10.1186/s12885-020-07386-z
BMC Cancer, 20(1):884. BioMed Central
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer, 20(1):884. BMC
BMC Cancer, 20
BMC Cancer, 20, 1
Privé, B M, Janssen, M J R, Van Oort, I M, Muselaers, C H J, Jonker, M A, De Groot, M, Mehra, N, Verzijlbergen, J F, Scheenen, T W J, Zámecnik, P, Barentsz, J O, Gotthardt, M, Noordzij, W, Vogel, W V, Bergman, A M, Van Der Poel, H G, Vis, A N, Oprea-Lager, D E, Gerritsen, W R, Witjes, J A & Nagarajah, J 2020, ' Lutetium-177-PSMA-I &T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial ', BMC Cancer, vol. 20, no. 1, 884 . https://doi.org/10.1186/s12885-020-07386-z
BMC Cancer, 20(1):884. BioMed Central
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer, 20(1):884. BMC
Background In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone
Autor:
Goran Vuleta, Maurizio Dondi, Thomas Pascual, Diana Paez, Mario Medvedec, Claudiu Peștean, Urban Zdešar, Dean Pekarovič, Maximilien Vermandel, Hélène Lahousse, Leesa Ross, Dusty York, Giorgio Testanera, Michel de Groot, Aljaz Socan, Kristof Baete, Petra Kolenc Peitl, Marko Krošelj, Søren Holm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce0feef5356df924455568815fb1e2a6
https://doi.org/10.52717/ifsd3470
https://doi.org/10.52717/ifsd3470
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 32, 98-101
European Journal of Nuclear Medicine and Molecular Imaging, 32, 1, pp. 98-101
European Journal of Nuclear Medicine and Molecular Imaging, 32, 1, pp. 98-101
Contains fulltext : 48041.pdf (Publisher’s version ) (Closed access) PURPOSE: Increased, non-pathological FDG uptake in myocardium, stomach and bowel is frequently observed while performing clinical positron emission tomography (PET) studies. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57124a2cc7df8a5ca40da17fb9538aa2
http://hdl.handle.net/2066/48041
http://hdl.handle.net/2066/48041
Autor:
Daniel P. Duarte, Éden R. Ferreira, Fabio M. Lima, Franciane Batista, Michel De Groote, Eduardo Horjales, Luiz C. Miletti, Diana Bahia
Publikováno v:
Frontiers in Cellular and Infection Microbiology, Vol 8 (2018)
The mevalonate pathway is an essential part of isoprenoid biosynthesis leading to production of a diverse class of >30,000 biomolecules including cholesterol, heme, and all steroid hormones. In trypanosomatids, the mevalonate pathway also generates d
Externí odkaz:
https://doaj.org/article/2034eea0dc56480fa5195345cfb4deb7